Building on previously published research involving glass microspheres, a newly published study explores the delivery of embolic microspheres using the TriNav® Infusion System. This state-of-the-art preclinical research, published in the Journal of Vascular and Interventional

May is National Cancer Research Month - a time to honor the breakthroughs that move us closer to more effective treatments and better outcomes for cancer patients. At TriSalus Life Sciences, we’re committed to advancing the science of therapeutic delivery to solid tumors. Our

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐢𝐬 𝐣𝐮𝐬𝐭 𝐚𝐫𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐛𝐞𝐧𝐝! In just over two weeks, the 𝐓𝐫𝐢𝐍𝐚𝐯® 𝐈𝐧𝐟𝐮𝐬𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 is expanding—with more flexibility than ever before. Stay tuned as we unveil the next innovation in precision

TriNav® Case Snippets are real-world examples of how Interventional Radiologists are using the TriNav Infusion System. Our latest case demonstrates how one physician used TriNav LV to improve the T:N ratio while decreasing background liver uptake during treatment of metastatic

We are thrilled to announce the newest addition to the TriNav portfolio - The 𝐓𝐫𝐢𝐍𝐚𝐯 𝐅𝐋𝐗 𝐈𝐧𝐟𝐮𝐬𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦 will be launching soon! Engineered for enhanced trackability, 𝐓𝐫𝐢𝐍𝐚𝐯 𝐅𝐋𝐗 features a more flexible distal tip, suited for cases where

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System! Read the Full Press Release Here: na2.hubs.ly/y0gdkc0

🚀 Exciting News! 🚀 We are thrilled to announce the launch of the 𝐓𝐫𝐢𝐍𝐚𝐯 𝐅𝐋𝐗 𝐈𝐧𝐟𝐮𝐬𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦, the latest addition to the TriNav portfolio! TriNav FLX offers: ✨ Enhanced trackability with twice the length of more flexible material at the distal tip for

For many patients, sparing healthy liver can be just as important as delivering more therapy to the tumor, particularly in complex patients with higher disease burden and/or reduced liver function. Click below to learn more about studies that demonstrate the impact the

The TriNav Infusion System Portfolio — now with TriNav, TriNav LV, and the new TriNav FLX. Our expanded portfolio aims to empower Interventional Radiologists to target tumors more precisely with the Pressure-Enabled Drug Delivery™ (PEDD™) approach. TriNav is designed to

June is National Cancer Survivor Month At TriSalus Life Sciences, we are honored to recognize and celebrate the strength, resilience, and hope of the millions of individuals living with and beyond cancer. Every survivor's story fuels our commitment to advancing innovative

As drug delivery approaches for solid tumors continues to advance, understanding how therapies are used in real-world settings is critical. A recent analysis of U.S. claims data offers valuable perspective on patient characteristics and treatment patterns across embolization

A growing body of evidence highlights advancements in therapeutic delivery with TriNav® and the Pressure-Enabled Drug Delivery Approach. Explore resources on the TriNav® Infusion System website to learn more: na2.hubs.ly/y0mtQK0 #TriNav #InterventionalRadiology #Oncology

Wishing you a safe and happy 4th of July! From all of us at TriSalus Life Sciences—have a great holiday!

See how the TriNav® Infusion System is designed to enhance precision in liver cancer therapy delivery. In a case TriNav® delivered segmental glass Y90 TARE to a 3cm HCC, achieving improved tumor penetration and coverage vs. a traditional microcatheter. na2.hubs.ly/y0sphm0

If you are ready to learn more about 𝐓𝐫𝐢𝐍𝐚𝐯® and 𝐏𝐫𝐞𝐬𝐬𝐮𝐫𝐞-𝐄𝐧𝐚𝐛𝐥𝐞𝐝 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲ᵀᴹ (𝐏𝐄𝐃𝐃ᵀᴹ), our dedicated team can provide: • A live demonstration of TriNav’s capabilities • Insights on integration into your practice • A

We recently introduced the TriNav FLX Infusion System, the newest advancement in Pressure-Enabled Drug Deliveryᵀᴹ (PEDDᵀᴹ) for solid tumors. TriNav FLX is designed for enhanced trackability with increased distal flexibility. Learn more about how TriNav FLX aims to enhance

The TriNav® Infusion System has a unique procedural HCPCS code for both treatment and mapping procedures, applicable to all payers. 🔹 Treatment Code: C9797 - Level 4 endovascular procedure, reimbursed at $17,957 🔹 Transarterial Radioembolization Mapping Code: C8004 - Level 3

REIMBURSEMENT UPDATE: We are pleased to announce our partnership with Z Health, offering a comprehensive suite of personalized reimbursement resources to support TriNav® users. Through the Ask Z Health Portal, healthcare professionals can access: • Timely responses to

Are you ready to explore innovative methods in therapy delivery for liver tumors? Check out this study that highlights the potential of Pressure-Enabled Drug Delivery™ (PEDD) to improve therapeutic delivery. Read the full study here to learn more about this approach and its